Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Diagnos Inc. is a Canadian medical technology company focused on the development and commercialization of computer‑assisted diagnostic software for the early detection of disease. The company operates primarily within the medical imaging and healthcare diagnostics industry, with a strategic emphasis on leveraging artificial intelligence (AI) and image‑processing algorithms to support clinicians in identifying pathological conditions at an early stage.
The company’s core technology platform, branded as CARA (Computer Assisted Retina Analysis), is designed to analyze retinal images to detect early signs of diabetic retinopathy and other eye‑related diseases. Diagnos Inc. positions itself as a non‑invasive, software‑driven diagnostics provider targeting healthcare systems seeking scalable screening solutions. Founded in 1998, the company has evolved from a broader medical imaging focus to a more specialized AI‑enabled diagnostics strategy, reflecting industry trends toward preventive care and automation.
Business Operations
Diagnos Inc. generates revenue primarily through the development, licensing, and commercialization of its CARA diagnostic software, which is intended for use by ophthalmologists, optometrists, clinics, and healthcare institutions. The software integrates with existing retinal imaging hardware and applies proprietary algorithms to assist clinicians in identifying disease markers, reducing diagnostic variability and improving screening efficiency.
Operationally, the company maintains research and development activities centered in Canada, while pursuing commercialization through partnerships and pilot programs in North America, Europe, and selected emerging markets. Diagnos Inc. does not manufacture hardware; instead, it focuses on software development, regulatory validation, and clinical adoption. Public disclosures indicate limited large‑scale commercial deployment to date, with revenues historically reflecting early‑stage commercialization and development‑phase operations.
Strategic Position & Investments
Diagnos Inc.’s strategic direction centers on expanding the clinical adoption of AI‑driven retinal diagnostics, particularly for chronic diseases such as diabetes, where early detection is critical to patient outcomes and healthcare cost reduction. Growth initiatives have focused on obtaining regulatory clearances, enhancing algorithm accuracy through clinical data, and establishing distribution relationships with healthcare providers and imaging equipment users.
The company has historically emphasized organic development over large acquisitions, with no material acquisitions publicly confirmed in recent filings. Its investment priorities remain concentrated on software refinement, clinical validation studies, and selective international market entry. While the company references potential applications of its technology beyond ophthalmology, publicly available information indicates that retinal diagnostics remain its primary and verified commercial focus.
Geographic Footprint
Diagnos Inc. is headquartered in Canada, where it conducts corporate management, research, and development activities. The company’s primary operational base supports both domestic commercialization efforts and international outreach.
Internationally, Diagnos Inc. has reported market engagement activities in North America, Europe, and parts of Asia and Latin America, largely through distributors, pilot projects, and clinical collaborations rather than wholly owned foreign subsidiaries. Its global footprint is best characterized as exploratory and partnership‑driven, with limited permanent infrastructure outside Canada.
Leadership & Governance
Diagnos Inc. is led by a management team with experience in medical technology, software development, and healthcare commercialization. The company’s leadership emphasizes innovation in preventive diagnostics and the application of AI to improve clinical decision‑making while maintaining regulatory compliance.
Key executives include:
- André Larente – President and Chief Executive Officer
- Christian Bessette – Chief Financial Officer
- Pierre Deschamps – Chairman of the Board
- Jacques Drouin – Director
The leadership team’s stated strategic vision focuses on positioning Diagnos Inc. as a specialized provider of AI‑enabled diagnostic tools that can be integrated into existing healthcare workflows, with an emphasis on long‑term clinical value rather than short‑term scale.